SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals. SHINE has provided the first supply of Ilumira – its non-carrier added lutetium-177 (n.c.a. Lu-177) chloride – to Blue Earth Therapeutics that will be used in clinical trials to assess a potential treatment for men with prostate cancer. This partnership follows SHINE’s submission of a Drug Master File to the U.S. Food and Drug Administration – enabling SHINE to be on a fast track to deliver for its customers.

The American Cancer Society estimates that there will be nearly 300K new cases of prostate cancer in the United States this year and over 35K deaths. Statistically, approximately 12.9% of men will be diagnosed with prostate cancer at some point during their lifetime. Blue Earth Therapeutics aims to develop a best-in-class therapy for prostate cancer. Radiopharmaceuticals allow for targeted treatment with the intent to localize therapy to tumors while minimizing effects on healthy tissue.

N.c.a Lu-177 has historically faced significant challenges in its supply chain. There are a limited number of reactors producing n.c.a. Lu-177 and continuous supply is a challenge. Located in North America, SHINE has the greatest production capacity for n.c.a. Lu-177 in the United States, uses a proprietary production process that’s more efficient and environmentally friendly, and is one of the only producers of ytterbium-176 at scale outside of Russia.

Click here to read the full article.